Inflammation programs – Cristal Therapeutics

Programs

Inflammation programs

CPC289 is designed to be a best-in-drug class treatment for inflammation.

CPC289 is a CriPec^®-based nanoparticle incorporating dexamethasone, an approved corticosteroid therapeutic for the treatment of inflammation. Compared with standard systemic dexamethasone treatments, CPC289 is designed to target a chronic inflammation site more effectively and enable improved sustained drug release.

By specifically targeting the site of chronic inflammation with a defined drug payload, CPC289 aims to overcome the low efficacy, limited half-life and multiple off-target toxicities routinely seen with dexamethasone.

Furthermore, additional studies suggest that this effect does not seem to be specific for CPC289, but is expected to hold true for all corticosteroids.

CPC289 is ready for pre-clinical development and is available for partnering.

Arthritis models

Compared to conventional dexamethasone treatment, CPC289 demonstrated a superior efficacy in both rat and mice arthritis models. This result is attributed to the enhanced accumulation of CPC289 at the inflammation site, combined with well-controlled drug release.

Data show superior efficacy combined with excellent tolerability results. This was confirmed by uCT images, bone mineral density measurements and histology.